Smoking cessation: the evidence-based approach for Australian GPs

Smoking cessation — the highest-yield intervention in Australian general practice

Tobacco smoking is Australia’s leading preventable cause of death and disease. AIHW attributes approximately 19,000 deaths per year to tobacco — approximately 13% of all Australian deaths — and estimates it contributes to 87% of lung cancers, 70% of COPD, substantially elevated cardiovascular mortality (2–4 times), and cancers of the head and neck, oesophagus, stomach, pancreas, bladder, cervix, and kidney.

Daily smoking prevalence has fallen from approximately 25% in 1990 to about 10% in 2022–23 — a public health success driven by taxation, advertising restrictions, plain packaging, and the RACGP Supporting Smoking Cessation guideline. However, rates remain approximately 37% among Aboriginal and Torres Strait Islander adults, making culturally tailored cessation programs a public health priority. Nicotine vaping is rising sharply in younger Australians, introducing a new form of dependence.

Cessation benefits accrue rapidly: exhaled carbon monoxide normalises within 24 hours, lung function begins improving within 2 weeks, cardiovascular risk halves within 1 year, and lung cancer risk halves within 10 years. Even late-stage smoking cessation — after established COPD or ischaemic heart disease — meaningfully reduces disease progression and mortality.

A. Core clinical — the AU general-practice framework

Dependence assessment

Nicotine dependence (ICD-10 F17; DSM-5 tobacco use disorder) is a chronic relapsing disorder with compulsive use, tolerance, and withdrawal. Assessment uses the Fagerström Test for Nicotine Dependence — a score ≥6 indicates high dependence, with the two highest-yield questions being time-to-first-cigarette (<30 minutes indicates high dependence) and cigarettes per day. eTG and AMH both recommend Fagerström scoring to guide pharmacotherapy intensity.

Readiness is assessed using the Prochaska stages: precontemplation → contemplation → preparation → action → maintenance. Different consultation approaches suit different stages — motivational interviewing for precontemplation, practical planning for preparation and action.

The 5As at every consultation

The RACGP Supporting Smoking Cessation guideline (2024) recommends the 5As:

1. Ask — smoking and vaping status at every visit; document in the health record; include both tobacco and nicotine vaping
2. Advise — clear, strong, personalised: “As your GP, the single most important thing you can do for your health right now is stop smoking”
3. Assess — readiness (Prochaska stage), dependence (Fagerström), prior quit attempts and what helped or triggered relapse
4. Assist — agree a quit date; choose pharmacotherapy; provide a Quitline 13 78 48 warm referral; identify triggers; plan substitutes
5. Arrange — follow-up at 1–2 weeks then monthly; reframe any relapse as iteration not failure

Stead et al. (Cochrane 2013) demonstrated that even 1-minute brief advice from a GP increases quit rates by approximately 2% — significant at a population level given the number of smokers seen in general practice.

Pharmacotherapy — first-line options

Per eTG and AMH:

Combination NRT (patch + short-acting) — the most effective NRT regimen per Lindson Cochrane 2019:

• Patch: 21 mg (24-hour) or 25 mg (16-hour) for smokers of ≥10 cigarettes/day; step down over 8–12 weeks
• Short-acting (gum 2/4 mg, lozenge 1.5/2/4 mg, inhaler 15 mg, mouth spray 1 mg/puff) — up to 15 doses per day for breakthrough cravings
• PBS Authority Streamlined (Aboriginal and Torres Strait Islander, concession cardholders, people with chronic mental illness) — one 12-week course per year; combination acceptable on a single Authority

Varenicline (Champix) — the most effective single agent:

• α4β2 nicotinic partial agonist; reduces craving and withdrawal while blocking reward from continued smoking
• Dose: 0.5 mg daily × 3 days → 0.5 mg twice daily × 4 days → 1 mg twice daily; start 1 week before quit date
• PBS Authority Streamlined — 12 weeks; extension to 24 weeks with documented response and Quitline or clinician counselling per NPS RADAR
• Avoid in pregnancy and breastfeeding; neuropsychiatric monitoring per informed consent

Bupropion (Zyban SR) 150 mg — atypical antidepressant; PBS Authority Streamlined for cessation; useful when comorbid depression is present. Contraindicated in seizure disorder, eating disorders, and abrupt withdrawal from alcohol or benzodiazepines.

B. Evidence appraisal — what works and what does not

Varenicline versus NRT — the EAGLES evidence

The EAGLES trial (Anthenelli Lancet 2016) — 8,144 smokers including 4,116 with stable psychiatric conditions — compared varenicline, bupropion, nicotine patch, and placebo. Varenicline achieved the highest quit rates (~21% sustained abstinence at 9–24 weeks versus ~13% for patch and ~11% for bupropion). Crucially, no significant increase in serious neuropsychiatric adverse events was found for varenicline versus placebo in either the psychiatric or non-psychiatric cohorts. This evidence supports offering varenicline to people with stable mental illness with appropriate monitoring.

Nicotine vaping products for cessation

Hartmann-Boyce et al. (Cochrane 2024) — 88 studies, >27,000 participants — found moderate-certainty evidence that nicotine vaping products increase short-term quit rates compared with NRT. The TGA October 2024 reforms moved NVPs to Schedule 4, allowing pharmacist supply without prescription for adults ≥18. RACGP 2024 does not position NVPs as first-line; they remain a reserve option when standard pharmacotherapy plus behavioural support has failed. Long-term pulmonary and cardiovascular safety is unknown. NVPs should be actively discouraged in adolescents and never-smokers.

Brief intervention evidence

Stead Cochrane 2013 established that brief physician advice — even under a minute — increases population quit rates by approximately 2%. Given the volume of smokers seen in Australian general practice each year, systematic 5As implementation has substantial public health impact. The Ottawa model of brief intervention is recommended in eTG.

C. Behavioural support and relapse prevention

Quitline and digital tools

Quitline 13 78 48 provides free, evidence-based telephone counselling. A GP warm transfer — introducing the Quitline counsellor during the consultation or directly facilitating the call — substantially increases uptake compared with giving a number to call later. Quitline offers pregnancy-specific, Aboriginal and Torres Strait Islander-specific, and multilingual lines.

myQuitBuddy app (Australian Government) and iCanQuit (Cancer Council) provide free evidence-informed digital support. CBT for nicotine dependence, funded via a Mental Health Care Plan (MBS 2715/2717) with comorbid mental health diagnosis, provides trigger management, urge surfing, and relapse prevention skills.

Relapse prevention

Most quitters need 5–30 attempts before sustained abstinence. Relapse is most common in the first 2 weeks after the quit date. Key triggers include alcohol, social contexts, stress, mealtimes, and driving. At the follow-up visit (1–2 weeks post-quit-date), review withdrawal symptoms and adherence; address specific triggers; encourage without judgement. Weight gain is a common concern — aerobic exercise 150 minutes/week partially offsets it and independently reduces cravings. Ussher Cochrane 2014 found modest benefit of exercise on craving and withdrawal.

D. Australian operations

PBS listings

Per PBS (verified 2026-06-04):

• Varenicline (Champix) — Authority Streamlined; 12 weeks + 12-week extension
• Bupropion (Zyban SR 150 mg) — Authority Streamlined for smoking cessation
• NRT (patches, gum, lozenges, inhaler, spray) — Authority Streamlined for Aboriginal and Torres Strait Islander patients, concession cardholders, and people with chronic mental illness; free via Closing the Gap PBS Co-payment Program for First Nations patients
• Nicotine vaping products — Schedule 4 since October 2024; pharmacist supply, not PBS-subsidised

MBS billing

Standard consults 23/36/44; GPCCMP (Chronic Condition Management Plan) 965/967 where nicotine dependence is combined with COPD, ischaemic heart disease, or mental health disorder; Mental Health Care Plan 2715/2717 for comorbid depression or anxiety with 10 CBT sessions/year; ATSI Health Assessment 715 includes smoking review; 75+ health assessment 705; spirometry 11506 if ≥10 pack-years or respiratory symptoms; practice nurse 10997 for nurse-led cessation support under GPCCMP.

National Lung Cancer Screening Program

The National Lung Cancer Screening Program — commenced July 2025 — offers low-dose CT screening for current or former smokers aged 50–70 years with ≥30 pack-years. GPs play a central role in identifying eligible patients and facilitating referral. Cessation should always accompany screening; continuing to smoke while screening reduces the mortality benefit.

Tackling Indigenous Smoking

The Tackling Indigenous Smoking program provides community-led, culturally tailored cessation support. Whittaker et al. (BMJ Open 2021) demonstrated effectiveness of these programs. Aboriginal Health Workers are central; refer and collaborate rather than working in isolation.

E. Special populations

Pregnancy: Cessation is the single most effective intervention for fetal and infant wellbeing. Behavioural support via Quitline (pregnancy line) is primary. Intermittent short-acting NRT (lozenge or gum) is cautiously acceptable when behaviour change alone is insufficient — lower dose, remove patch overnight if using continuous. Avoid varenicline and bupropion. Document cessation counselling at every antenatal visit.

Severe mental illness: Smoking rates 2–3 times higher; cessation is safe and improves long-term mental health outcomes per EAGLES 2016. Do not initiate cessation during acute psychiatric crisis. Coordinate with psychiatrist. Varenicline is the agent of choice in stable mental illness with appropriate monitoring. MHCP-funded CBT supports the cessation attempt.

Adolescents and young adults: Vaping nicotine dependence is increasingly common. Address at every consultation; involve parents where appropriate. Pharmacotherapy under 18 requires specialist input. Focus on harm reduction, peer influence, and building intrinsic motivation.

Aboriginal and Torres Strait Islander patients: Engage with Tackling Indigenous Smoking program, Aboriginal Community Controlled Health Organisations, and Aboriginal Health Workers. Free NRT via Closing the Gap PBS Co-payment Program. Cultural dimensions of tobacco use — ceremony, social bonding — require culturally safe discussion.

When to escalate

Refer or seek support when:

• Two or more evidence-based quit attempts with combination pharmacotherapy have failed — consider addiction medicine, respiratory, or specialist smoking cessation clinic
• Complex psychiatric comorbidity requiring coordinated care — psychiatry + GP collaboration
• Pregnancy with high dependence or pharmacotherapy questions — obstetric or addiction medicine input
• Suspected smoking-related cancer (haemoptysis, hoarseness, persistent cough, weight loss, haematuria) — urgent investigation regardless of cessation status

What this article is and is not

This is general health information based on the RACGP Supporting Smoking Cessation guideline (2024), eTG, AMH, Cochrane reviews, and the EAGLES trial. It does not constitute personal medical advice and does not create a doctor–patient relationship. Pharmacotherapy choices, PBS Authority prescriptions, and mental health care plans are decided with your treating GP.

For Australian consumer resources: Quit Australia — Quitline 13 78 48, HealthDirect — Quit smoking, myQuitBuddy app, iCanQuit.

---

Sources cited

1. RACGP — Supporting smoking cessation (2024)
2. Therapeutic Guidelines (eTG) — Smoking cessation
3. Australian Medicines Handbook
4. NPS MedicineWise — Varenicline 24-week PBS
5. TGA Vaping Hub — October 2024 reforms
6. AIHW — Tobacco smoking in Australia
7. Quit Australia — Quitline 13 78 48
8. Cancer Council — Smoking
9. Tackling Indigenous Smoking program
10. National Lung Cancer Screening Program
11. HealthDirect — Quit smoking
12. myQuitBuddy app
13. Anthenelli et al. — EAGLES (Lancet 2016)
14. Lindson et al. — Combination NRT (Cochrane 2019)
15. Hartmann-Boyce et al. — E-cigarettes for cessation (Cochrane 2024)
16. Stead et al. — Physician advice for cessation (Cochrane 2013)
17. Ussher et al. — Exercise for smoking cessation (Cochrane 2014)